{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:57:03Z","timestamp":1788177423776,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T00:00:00Z","timestamp":1384819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1038\/nrgastro.2013.216","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T09:45:26Z","timestamp":1384854326000},"page":"209-219","source":"Crossref","is-referenced-by-count":210,"title":["Management of patients with hepatitis B who require immunosuppressive therapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Jessica P.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.-F.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"key":"BFnrgastro2013216_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.6004\/jnccn.2011.0045","volume":"9","author":"B Keam","year":"2011","unstructured":"Keam, B., Lee, J. H., Im, S. A. & Yoon, J. H. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J. Natl Compr. Canc. Netw. 9, 465\u2013477 (2011).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"BFnrgastro2013216_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nrrheum.2012.63","volume":"8","author":"D Vassilopoulos","year":"2012","unstructured":"Vassilopoulos, D. & Calabrese, L. H. Management of rheumatic disease with comorbid HBV or HCV infection. Nat. Rev. Rheumatol. 8, 348\u2013357 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrgastro2013216_CR3","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1053\/jhep.2002.36156","volume":"36","author":"TM Chan","year":"2002","unstructured":"Chan, T. M. et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 36, 1246\u20131252 (2002).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/14712598.2012.646986","volume":"12","author":"M Vigano","year":"2012","unstructured":"Vigano, M., Degasperi, E., Aghemo, A., Lampertico, P. & Colombo, M. Anti-TNF drugs in patients with hepatitis B or C virus infection: Safety and clinical management. Expert Opin. Biol. Ther. 12, 193\u2013207 (2012).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFnrgastro2013216_CR5","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle, J. H. Reactivation of hepatitis B. Hepatology 49, S156\u2013S165 (2009).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","volume":"148","author":"R Loomba","year":"2008","unstructured":"Loomba, R. et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 148, 519\u2013528 (2008).","journal-title":"Ann. Intern. Med."},{"key":"BFnrgastro2013216_CR7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2036.2009.04158.x","volume":"31","author":"TT Tran","year":"2010","unstructured":"Tran, T. T., Rakoski, M. O., Martin, P. & Poordad, F. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment. Pharmacol. Ther. 31, 240\u2013246 (2010).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2013216_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JOP.2010.000133","volume":"7","author":"FL Day","year":"2011","unstructured":"Day, F. L., Link, E., Thursky, K. & Rischin, D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J. Oncol. Pract. 7, 141\u2013147 (2011).","journal-title":"J. Oncol. Pract."},{"key":"BFnrgastro2013216_CR9","first-page":"1","volume":"57","author":"CM Weinbaum","year":"2008","unstructured":"Weinbaum, C. M. et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 57, 1\u201320 (2008).","journal-title":"MMWR Recomm. Rep."},{"key":"BFnrgastro2013216_CR10","doi-asserted-by":"crossref","unstructured":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 57, 167\u2013185 (2012).","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"BFnrgastro2013216_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw, Y. F. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol. Int. 6, 531\u2013561 (2012).","journal-title":"Hepatol. Int."},{"key":"BFnrgastro2013216_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"ASF Lok","year":"2009","unstructured":"Lok, A. S. F. & McMahon, B. J. AASLD practice guideline update: chronic hepatitis B: update 2009. Hepatology 50, 661\u2013662 (2009).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR13","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","volume":"28","author":"AS Artz","year":"2010","unstructured":"Artz, A. S. et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J. Clin. Oncol. 28, 3199\u20133202 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2013216_CR14","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","volume":"10","author":"LR Baden","year":"2012","unstructured":"Baden, L. R. et al. Prevention and treatment of cancer-related infections. J. Natl Compr. Canc. Netw. 10, 1412\u20131445 (2012).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"BFnrgastro2013216_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/hep.1840360617","volume":"36","author":"CJ Chu","year":"2002","unstructured":"Chu, C. J., Hussain, M. & Lok, A. S. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 36, 1408\u20131415 (2002).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.1840180605","volume":"18","author":"TL Fong","year":"1993","unstructured":"Fong, T. L., Di Bisceglie, A. M., Gerber, M. A., Waggoner, J. G. & Hoofnagle, J. H. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 18, 1313\u20131318 (1993).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR17","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/nm1096-1104","volume":"2","author":"B Rehermann","year":"1996","unstructured":"Rehermann, B., Ferrari, C., Pasquinelli, C. & Chisari, F. V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2, 1104\u20131108 (1996).","journal-title":"Nat. Med."},{"key":"BFnrgastro2013216_CR18","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","volume":"31","author":"YH Huang","year":"2013","unstructured":"Huang, Y. H. et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J. Clin. Oncol. 31, 2765\u20132772 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2013216_CR19","doi-asserted-by":"publisher","unstructured":"Hsu, C. et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology http:\/\/dx.doi.org\/10.1002\/hep.26718 .","DOI":"10.1002\/hep.26718"},{"key":"BFnrgastro2013216_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.icb.7100009","volume":"85","author":"JJ Chang","year":"2007","unstructured":"Chang, J. J. & Lewin, S. R. Immunopathogenesis of hepatitis B virus infection. Immunol. Cell Biol. 85, 16\u201323 (2007).","journal-title":"Immunol. Cell Biol."},{"key":"BFnrgastro2013216_CR21","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1073\/pnas.83.6.1627","volume":"83","author":"R Tur-Kaspa","year":"1986","unstructured":"Tur-Kaspa, R., Burk, R. D., Shaul, Y. & Shafritz, D. A. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc. Natl Acad. Sci. USA 83, 1627\u20131631 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro2013216_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10067-010-1523-2","volume":"29","author":"MB Carroll","year":"2010","unstructured":"Carroll, M. B. & Forgione, M. A. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin. Rheumatol. 29, 1021\u20131029 (2010).","journal-title":"Clin. Rheumatol."},{"key":"BFnrgastro2013216_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","volume":"136","author":"G Lalazar","year":"2007","unstructured":"Lalazar, G., Rund, D. & Shouval, D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br. J. Haematol. 136, 699\u2013712 (2007).","journal-title":"Br. J. Haematol."},{"key":"BFnrgastro2013216_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","volume":"100","author":"AS Lok","year":"1991","unstructured":"Lok, A. S. et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100, 182\u2013188 (1991).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013216_CR25","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","volume":"22","author":"AM Evens","year":"2011","unstructured":"Evens, A. M. et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann. Oncol. 22, 1170\u20131180 (2011).","journal-title":"Ann. Oncol."},{"key":"BFnrgastro2013216_CR26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","volume":"15","author":"SP Hammond","year":"2009","unstructured":"Hammond, S. P. et al. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 15, 1049\u20131059 (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrgastro2013216_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo, W. et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 62, 299\u2013307 (2000).","journal-title":"J. Med. Virol."},{"key":"BFnrgastro2013216_CR28","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/annonc\/mdh430","volume":"15","author":"W Yeo","year":"2004","unstructured":"Yeo, W. et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann. Oncol. 15, 1661\u20131666 (2004).","journal-title":"Ann. Oncol."},{"key":"BFnrgastro2013216_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.21024","volume":"43","author":"JW Jang","year":"2006","unstructured":"Jang, J. W. et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43, 233\u2013240 (2006).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","volume":"131","author":"CK Hui","year":"2006","unstructured":"Hui, C. K. et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131, 59\u201368 (2006).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013216_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbmt.2005.09.001","volume":"12","author":"L-T Hsiao","year":"2006","unstructured":"Hsiao, L.-T. et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 12, 84\u201394 (2006).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrgastro2013216_CR32","unstructured":"American Association for the Study of Liver Diseases Emerging Trends Conference, Reactivation of Hepatitis B March 21\u201322, 2013; Arlington, VA (2013)."},{"key":"BFnrgastro2013216_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/jmv.10430","volume":"70","author":"W Yeo","year":"2003","unstructured":"Yeo, W. et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J. Med. Virol. 70, 553\u2013561 (2003).","journal-title":"J. Med. Virol."},{"key":"BFnrgastro2013216_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/bjc.2011.4","volume":"104","author":"J Yun","year":"2011","unstructured":"Yun, J. et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br. J. Cancer 104, 559\u2013563 (2011).","journal-title":"Br. J. Cancer"},{"key":"BFnrgastro2013216_CR35","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","volume":"90","author":"W Yeo","year":"2004","unstructured":"Yeo, W. et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer 90, 1306\u20131311 (2004).","journal-title":"Br. J. Cancer"},{"key":"BFnrgastro2013216_CR36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet, J. M. & Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37, 429\u2013442 (2003).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jhep.2012.09.021","volume":"58","author":"M Cescon","year":"2013","unstructured":"Cescon, M., Cucchetti, A., Ravaioli, M. & Pinna, A. D. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J. Hepatol. 58, 609\u2013618 (2013).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2013216_CR38","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/hep.24246","volume":"53","author":"R Golfieri","year":"2011","unstructured":"Golfieri, R. et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (&lt;5 cm) hepatocellular carcinomas. Hepatology 53, 1580\u20131589 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR39","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1872-034X.2011.00796.x","volume":"41","author":"X-M Lao","year":"2011","unstructured":"Lao, X.-M. et al. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatol. Res. 41, 553\u2013563 (2011).","journal-title":"Hepatol. Res."},{"key":"BFnrgastro2013216_CR40","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/sj.bmt.1704285","volume":"32","author":"V Gupta","year":"2003","unstructured":"Gupta, V., Lazarus, H. M. & Keating, A. Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant. 32, 969\u2013978 (2003).","journal-title":"Bone Marrow Transplant."},{"key":"BFnrgastro2013216_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s12185-013-1313-0","volume":"97","author":"SF Wahid","year":"2013","unstructured":"Wahid, S. F. Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies. Int. J. Hematol. 97, 581\u2013598 (2013).","journal-title":"Int. J. Hematol."},{"key":"BFnrgastro2013216_CR42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/sj.bmt.1700744","volume":"19","author":"GK Lau","year":"1997","unstructured":"Lau, G. K., Liang, R., Chiu, E. K., Lee, C. K. & Lam, S. K. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 19, 795\u2013799 (1997).","journal-title":"Bone Marrow Transplant."},{"key":"BFnrgastro2013216_CR43","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.bbmt.2011.04.006","volume":"17","author":"S Park","year":"2011","unstructured":"Park, S. et al. Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus. Biol. Blood Marrow Transplant. 17, 1630\u20131637 (2011).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrgastro2013216_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1703614","volume":"30","author":"P Seth","year":"2002","unstructured":"Seth, P. et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant. 30, 189\u2013194 (2002).","journal-title":"Bone Marrow Transplant."},{"key":"BFnrgastro2013216_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/bmt.2010.70","volume":"46","author":"M Vigano","year":"2011","unstructured":"Vigano, M. et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant. 46, 125\u2013131 (2011).","journal-title":"Bone Marrow Transplant."},{"key":"BFnrgastro2013216_CR46","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.bbmt.2009.12.532","volume":"16","author":"CA Ramos","year":"2010","unstructured":"Ramos, C. A. et al. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 16, 686\u2013694 (2010).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrgastro2013216_CR47","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1046\/j.1440-1746.2001.02532.x","volume":"16","author":"CJ Liu","year":"2001","unstructured":"Liu, C. J. et al. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience. J. Gastroenterol. Hepatol. 16, 1001\u20131008 (2001).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013216_CR48","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/hep.1840030309","volume":"3","author":"G Dusheiko","year":"1983","unstructured":"Dusheiko, G. et al. Natural history of hepatitis B virus infection in renal transplant recipients\u2014a fifteen-year follow-up. Hepatology 3, 330\u2013336 (1983).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR49","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/hep.510290123","volume":"29","author":"P Mathurin","year":"1999","unstructured":"Mathurin, P. et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29, 257\u2013263 (1999).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR50","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.trre.2011.02.001","volume":"25","author":"H Kalia","year":"2011","unstructured":"Kalia, H., Fabrizi, F. & Martin, P. Hepatitis B virus and renal transplantation. Transplant. Rev. (Orlando) 25, 102\u2013109 (2011).","journal-title":"Transplant. Rev. (Orlando)"},{"key":"BFnrgastro2013216_CR51","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jcv.2004.10.006","volume":"32","author":"A Berger","year":"2005","unstructured":"Berger, A., Preiser, W., Kachel, H. G., Sturmer, M. & Doerr, H. W. HBV reactivation after kidney transplantation. J. Clin. Virol. 32, 162\u2013165 (2005).","journal-title":"J. Clin. Virol."},{"key":"BFnrgastro2013216_CR52","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/tid.12065","volume":"15","author":"GD Chen","year":"2013","unstructured":"Chen, G. D., Gu, J. L., Qiu, J. & Chen, L. Z. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers. Transpl. Infect. Dis. 15, 300\u2013305 (2013).","journal-title":"Transpl. Infect. Dis."},{"key":"BFnrgastro2013216_CR53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S1053-2498(00)00362-4","volume":"20","author":"P Grossi","year":"2001","unstructured":"Grossi, P. et al. Prevalence and outcome of hepatitis B virus (HBV) infection following thoracic organ transplantation. J. Heart Lung Transplant. 20, 179 (2001).","journal-title":"J. Heart Lung Transplant."},{"key":"BFnrgastro2013216_CR54","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1053\/gast.2000.7951","volume":"119","author":"F Lunel","year":"2000","unstructured":"Lunel, F. et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 119, 1064\u20131074 (2000).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013216_CR55","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.athoracsur.2005.12.026","volume":"81","author":"AB Shitrit","year":"2006","unstructured":"Shitrit, A. B. et al. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann. Thorac. Surg. 81, 1851\u20131852 (2006).","journal-title":"Ann. Thorac. Surg."},{"key":"BFnrgastro2013216_CR56","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1097\/01.tp.0000176941.21438.95","volume":"80","author":"R Zampino","year":"2005","unstructured":"Zampino, R. et al. Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment. Transplantation 80, 1340\u20131343 (2005).","journal-title":"Transplantation"},{"key":"BFnrgastro2013216_CR57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","volume":"47","author":"JC Gea-Banacloche","year":"2010","unstructured":"Gea-Banacloche, J. C. Rituximab-associated infections. Semin. Hematol. 47, 187\u2013198 (2010).","journal-title":"Semin. Hematol."},{"key":"BFnrgastro2013216_CR58","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo, W. et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 27, 605\u2013611 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2013216_CR59","unstructured":"US Department of Health and Human Services. Product approval information\u2014licensing action. US Food and Drug Administration [online] , (1997)."},{"key":"BFnrgastro2013216_CR60","unstructured":"US Department of Health and Human Services. Approval history for arzerra. US Food and Drug Administration [online] , (2009)."},{"key":"BFnrgastro2013216_CR61","unstructured":"Nayernama, A. et al. Hepatitis B virus reactivation in CD20 antibody-treated patients: evaluation of post-market data from the FDA adverse event reporting system [abstract #8]. Presented at the American Association for the Study of Liver Diseases Emerging Trends Conference: Reactivation of Hepatitis B (2013)."},{"key":"BFnrgastro2013216_CR62","unstructured":"US Department of Health and Human Services. FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). US Food and Drug Administration [online] , (2013)."},{"key":"BFnrgastro2013216_CR63","unstructured":"US Department of Health and Human Services. Label information for rituximab. US Food and Drug Administration [online] , (2013)."},{"key":"BFnrgastro2013216_CR64","unstructured":"US Department of Health and Human Services. Label information for ofatumumab. US Food and Drug Administration [online] , (2013)."},{"key":"BFnrgastro2013216_CR65","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1600-0609.2004.00375.x","volume":"74","author":"E Iannitto","year":"2005","unstructured":"Iannitto, E. et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur. J. Haematol. 74, 254\u2013258 (2005).","journal-title":"Eur. J. Haematol."},{"key":"BFnrgastro2013216_CR66","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/jmv.20705","volume":"78","author":"SE Moses","year":"2006","unstructured":"Moses, S. E. et al. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J. Med. Virol. 78, 1560\u20131563 (2006).","journal-title":"J. Med. Virol."},{"key":"BFnrgastro2013216_CR67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","volume":"90","author":"R Perez-Alvarez","year":"2011","unstructured":"Perez-Alvarez, R. et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90, 359\u2013371 (2011).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrgastro2013216_CR68","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0016-5085(81)80002-9","volume":"81","author":"GH Scullard","year":"1981","unstructured":"Scullard, G. H., Smith, C. I., Merigan, T. C., Robinson, W. S. & Gregory, P. B. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81, 987\u2013991 (1981).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013216_CR69","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7326\/0003-4819-104-1-12","volume":"104","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle, J. H. et al. A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 104, 12\u201317 (1986).","journal-title":"Ann. Intern. Med."},{"key":"BFnrgastro2013216_CR70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1440-1746.1996.tb00051.x","volume":"11","author":"IS Sheen","year":"1996","unstructured":"Sheen, I. S., Liaw, Y. F., Lin, S. M. & Chu, C. M. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors. J. Gastroenterol. Hepatol. 11, 143\u2013147 (1996).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013216_CR71","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","volume":"37","author":"AL Cheng","year":"2003","unstructured":"Cheng, A. L. et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37, 1320\u20131328 (2003).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR72","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/0003-4819-112-5-381","volume":"112","author":"MA Flowers","year":"1990","unstructured":"Flowers, M. A. et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann. Intern. Med. 112, 381\u2013382 (1990).","journal-title":"Ann. Intern. Med."},{"key":"BFnrgastro2013216_CR73","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/acr.21990","volume":"65","author":"N Droz","year":"2013","unstructured":"Droz, N. et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res. (Hoboken) 65, 1504\u20131514 (2013).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrgastro2013216_CR74","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hon.2900080504","volume":"8","author":"RH Liang","year":"1990","unstructured":"Liang, R. H. et al. Hepatitis B infection in patients with lymphomas. Hematol. Oncol. 8, 261\u2013270 (1990).","journal-title":"Hematol. Oncol."},{"key":"BFnrgastro2013216_CR75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1440-1746.2012.07280.x","volume":"28","author":"W Yeo","year":"2013","unstructured":"Yeo, W. & Chan, H. L. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J. Gastroenterol. Hepatol. 28, 31\u201337 (2013).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013216_CR76","first-page":"3035","volume":"24","author":"CH Hsu","year":"2004","unstructured":"Hsu, C. H. et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res. 24, 3035\u20133040 (2004).","journal-title":"Anticancer Res."},{"key":"BFnrgastro2013216_CR77","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","volume":"99","author":"GK Lau","year":"2002","unstructured":"Lau, G. K. et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99, 2324\u20132330 (2002).","journal-title":"Blood"},{"key":"BFnrgastro2013216_CR78","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/j.1478-3231.2009.02071.x","volume":"29","author":"D Ferraro","year":"2009","unstructured":"Ferraro, D. et al. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable? Liver Int. 29, 1171\u20131177 (2009).","journal-title":"Liver Int."},{"key":"BFnrgastro2013216_CR79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jcv.2012.07.015","volume":"55","author":"N Kanaan","year":"2012","unstructured":"Kanaan, N. et al. Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. J. Clin. Virol. 55, 233\u2013238 (2012).","journal-title":"J. Clin. Virol."},{"key":"BFnrgastro2013216_CR80","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/01.TP.0000151661.52601.FB","volume":"79","author":"M Onozawa","year":"2005","unstructured":"Onozawa, M. et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79, 616\u2013619 (2005).","journal-title":"Transplantation"},{"key":"BFnrgastro2013216_CR81","volume-title":"Hepatitis and Liver Cancer: a National Strategy for Prevention and Control of Hepatitis B and C","author":"HM Colvin","year":"2010","unstructured":"Colvin, H. M. & Mitchel, A. E. Hepatitis and Liver Cancer: a National Strategy for Prevention and Control of Hepatitis B and C (National Academies Press, 2010)."},{"issue":"Suppl. 1","key":"BFnrgastro2013216_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2893.2011.01499.x","volume":"18","author":"A Hatzakis","year":"2011","unstructured":"Hatzakis, A. et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J. Viral Hepat. 18 (Suppl. 1), 1\u201316 (2011).","journal-title":"J. Viral Hepat."},{"key":"BFnrgastro2013216_CR83","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1200\/JOP.2011.000450","volume":"8","author":"JP Hwang","year":"2012","unstructured":"Hwang, J. P. et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. J. Oncol. Pract. 8, e32\u2013e39 (2012).","journal-title":"J. Oncol. Pract."},{"key":"BFnrgastro2013216_CR84","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/oxfordjournals.aje.a114680","volume":"126","author":"GM McQuillan","year":"1987","unstructured":"McQuillan, G. M. et al. Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population. Am. J. Epidemiol. 126, 484\u2013491 (1987).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrgastro2013216_CR85","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","volume":"125","author":"GK Lau","year":"2003","unstructured":"Lau, G. K. et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125, 1742\u20131749 (2003).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013216_CR86","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/hep.22106","volume":"47","author":"C Hsu","year":"2008","unstructured":"Hsu, C. et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 47, 844\u2013853 (2008).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR87","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1136\/ard.2010.148783","volume":"70","author":"JL Lan","year":"2011","unstructured":"Lan, J. L. et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann. Rheum. Dis. 70, 1719\u20131725 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrgastro2013216_CR88","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1136\/ard.2009.127233","volume":"69","author":"D Vassilopoulos","year":"2010","unstructured":"Vassilopoulos, D. et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann. Rheum. Dis. 69, 1352\u20131355 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrgastro2013216_CR89","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468\u2013475 (2013).","journal-title":"Lancet"},{"key":"BFnrgastro2013216_CR90","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney, D. J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49, 1503\u20131514 (2009).","journal-title":"Hepatology"},{"key":"BFnrgastro2013216_CR91","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","volume":"43","author":"BP Kearney","year":"2004","unstructured":"Kearney, B. P., Flaherty, J. F. & Shah, J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43, 595\u2013612 (2004).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrgastro2013216_CR92","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejphar.2007.11.007","volume":"579","author":"J Weiss","year":"2008","unstructured":"Weiss, J., Weis, N., Ketabi-Kiyanvash, N., Storch, C. H. & Haefeli, W. E. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur. J. Pharmacol. 579, 104\u2013109 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrgastro2013216_CR93","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper, R. D. et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin. Infect. Dis. 51, 496\u2013505 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrgastro2013216_CR94","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1365-2893.2010.01386.x","volume":"18","author":"HR Li","year":"2011","unstructured":"Li, H. R. et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J. Viral Hepat. 18, 877\u2013883 (2011).","journal-title":"J. Viral Hepat."},{"key":"BFnrgastro2013216_CR95","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1002\/cncr.25253","volume":"116","author":"K Matsue","year":"2010","unstructured":"Matsue, K. et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 116, 4769\u20134776 (2010).","journal-title":"Cancer"},{"key":"BFnrgastro2013216_CR96","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","volume":"141","author":"J Fung","year":"2011","unstructured":"Fung, J. et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 141, 1212\u20131219 (2011).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013216_CR97","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/gut.2005.070763","volume":"54","author":"CK Hui","year":"2005","unstructured":"Hui, C. K. et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54, 1597\u20131603 (2005).","journal-title":"Gut"},{"key":"BFnrgastro2013216_CR98","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00277-004-0899-y","volume":"83","author":"MS Dai","year":"2004","unstructured":"Dai, M. S., Chao, T. Y., Kao, W. Y., Shyu, R. Y. & Liu, T. M. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann. Hematol. 83, 769\u2013774 (2004).","journal-title":"Ann. Hematol."},{"key":"BFnrgastro2013216_CR99","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.3748\/wjg.v17.i25.3069","volume":"17","author":"T Noterdaeme","year":"2011","unstructured":"Noterdaeme, T. et al. Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients. World J. Gastroenterol. 17, 3069\u20133072 (2011).","journal-title":"World J. Gastroenterol."}],"container-title":["Nature Reviews Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2013.216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2013.216","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2013.216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T18:48:12Z","timestamp":1716144492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2013.216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,19]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["BFnrgastro2013216"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2013.216","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,19]]}}}